Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers Academic Article uri icon

Overview

MeSH Major

  • Basic Helix-Loop-Helix Transcription Factors
  • Carcinoma, Non-Small-Cell Lung
  • DNA Methylation
  • Lung Neoplasms

abstract

  • Hypermethylation and decreased expression of TCF21 were tumor specific and very frequent in all NSCLCs, even early-stage disease, thus making TCF21 a potential candidate methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.

publication date

  • February 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3023841

Digital Object Identifier (DOI)

  • 10.1002/cncr.25472

PubMed ID

  • 20945327

Additional Document Info

start page

  • 606

end page

  • 17

volume

  • 117

number

  • 3